Kazakhstan Toxicological Study Requirements for Medical Devices: Scope, Triggers and Evidence Gaps

1. Key takeaways

The toxicological study results in a Kazakh registration dossier are an independent document item enumerated by Order No. ҚР ДСМ-16. Whether toxicological studies are required depends on the nature of contact (whether the device contacts the human body), the site and duration of contact (surface contact, body orifice access or implantation; short-term or long-term), and the material characteristics (whether extractables and leachables are present, whether the device is drug-containing, whether it is absorbable). The decision logic mirrors the internationally accepted approach to biological evaluation: material characterization and evaluation of existing data come first, and where the literature and equivalence reasoning can close the gaps, repeating tests is unnecessary; only where a genuine data gap remains are the corresponding studies commissioned according to the nature of contact. Framing toxicology this way converts it from a fixed cost into a targeted, defensible one.

2. Legal basis

3. Expert insights

Insight one: toxicological studies are a gap-filling instrument, not a routine test package. The internationally accepted biological evaluation pathway runs from material characterization, through evaluation of existing data including clinical use history, published literature and supplier data, to identification of data gaps, and only then to targeted testing. Rerunning the full panel of tests increases cost and lengthens the timeline, and it is not necessarily more convincing to the reviewer than a rigorous characterization plus reasoned justification. The reviewer evaluates the quality of the argument, not the quantity of certificates attached to it. In practice, a well-argued characterization report with a documented rationale for each omitted endpoint is accepted faster than a stack of generic test reports, because the reviewer can verify the reasoning chain instead of reinterpreting raw data.

Insight two: the nature of contact determines the test items, not the risk class alone. Two devices of the same class 2б can differ enormously in their biological evaluation programs: a surface-contact device and an implant carry entirely different endpoints. The GRZAN practice is to establish a contact matrix first, crossing the contact site with the contact duration, and to derive the test program from that matrix rather than applying a blanket rule by risk class. This avoids both under-testing, which triggers deficiency letters, and over-testing, which wastes budget and calendar time. The matrix also gives the reviewer a transparent rationale for why each endpoint was included or excluded, which shortens the biological evaluation discussion considerably.

Insight three: drug-containing and absorbable devices are special complexity cases. For drug-combination products, the toxicological evaluation must consider local and systemic exposure to the drug component; for absorbable devices, the toxicokinetics of degradation products must be addressed. The evaluation plans for these two categories should be discussed and agreed with the expert organization at the project initiation stage, because retrofitting an evaluation design after testing has begun is expensive and rarely persuasive. Budgeting for these studies separately, and securing a written position from the expert organization on the minimum dataset, keeps the project plan honest.

Insight four: sterilization residues are a high-frequency line of questioning. Ethylene oxide residues and radiation-induced material changes arise constantly in review, yet they are often not covered in depth in the home-market evaluation. Preparing sterilization validation and residue data in advance closes a common deficiency loop in one round, whereas discovering the gap after submission typically costs an entire supplementation cycle. Including these data in the sterilization validation file from the beginning, with methods and limits stated explicitly, makes the section self-evident to the reviewer rather than a subject of negotiation.

Insight five: confirm the qualifications of the testing institution and the reporting conventions in advance. For the same reasons that apply to technical testing, the institutional qualifications, acceptance criteria and report format for toxicological studies should be confirmed in writing before samples are shipped, so that the resulting reports are accepted at face value by the reviewer rather than challenged or disregarded late in the procedure.

4. Practical recommendations

1. Perform material characterization and evaluation of existing data first, identify the genuine gaps, and only then define the test program.
2. Derive test items from the matrix of contact site and contact duration rather than applying a blanket rule by risk class.
3. Engage the expert organization on the evaluation plan for drug-containing and absorbable devices at the project initiation stage.
4. Prepare sterilization validation and residue data in advance, covering both ethylene oxide and radiation processes.
5. Confirm the qualifications of the testing institution and the reporting conventions in writing before samples are shipped.

5. Verification checklist

• □ Material characterization and evaluation of existing data are complete and data gaps are identified
• □ The contact matrix of site and duration is established and the test program is derived from it
• □ Evaluation plans for drug-containing and absorbable devices have been pre-agreed with the expert organization
• □ Sterilization validation and residue data are complete
• □ Institutional qualifications and reporting conventions are confirmed in writing
• □ Toxicological study results are filed in the registration dossier as an independent document item

GRZAN provides registration support in Kazakhstan for manufacturers, importers and authorized representatives, covering biological evaluation strategy, toxicological study coordination and expert review liaison. For assistance, contact info@grzanglobal.com.

Regulatory information verified as of October 29, 2026.